Table 3.
Predicted annual ASCVD deaths prevented and additional cases of diabetes and myopathy from statin use among participants 40–75 years, without diabetes and with ≥7.5% 10-year ASCVD risk—NHANES 2005–2010
| Characteristic | Population* (100 000) | Eligible population† (100 000) | Estimated annual ASCVD deaths | ASCVD deaths prevented (95% CI) | Excess number diabetes (95% CI) | RCT-based additional cases of myopathy (95% CI)‡ | Population-based additional cases of myopathy (95% CI)§ |
|---|---|---|---|---|---|---|---|
| Total | 206.2 | 164.8 | 39 880 | 5425 (1276 to 8935) | 16 406 (4922 to 26 250) | 1030 (0 to 4791) | 24 302 (19 363 to 30 292) |
| Women | 66.6 | 51.1 | 12 500 | 1661 (391 to 2736) | 5093 (1528 to 8149) | 320 (0 to 1487) | 3219 (2221 to 4479) |
| Age group | |||||||
| 40–49 | 2.3 | 2.3 | 73 | 12 (3 to 20) | 232 (70 to 371) | 15 (0 to 68) | 146 (101 to 204) |
| 50–59 | 4.2 | 3.3 | 340 | 47 (11 to 78) | 331 (99 to 529) | 21 (0 to 97) | 209 (144 to 291) |
| 60–69 | 31.9 | 25.3 | 4670 | 653 (154 to 1075) | 2514 (754 to 4022) | 158 (0 to 734) | 1589 (1096 to 2211) |
| 70–75 | 28.2 | 20.2 | 7420 | 949 (223 to 1563) | 1994 (598 to 3191) | 125 (0 to 582) | 1260 (870 to 1754) |
| Race/ethnicity | |||||||
| Non-Hispanic white | 51.1 | 39.1 | 9270 | 1230 (289 to 2025) | 3897 (1169 to 6235) | 245 (0 to 1138) | 2463 (1700 to 3427) |
| Non-Hispanic black | 6.7 | 5.2 | 2070 | 277 (65 to 455) | 516 (155 to 825) | 32 (0 to 151) | 326 (225 to 453) |
| Hispanic | 5.4 | 4.2 | 777 | 103 (24 to 170) | 416 (125 to 666) | 26 (0 to 122) | 263 (182 to 366) |
| Men | 139.6 | 113.7 | 27 380 | 3764 (886 to 6199) | 11 313 (3394 to 18 101) | 711 (0 to 3304) | 21 084 (17 142 to 25 813) |
| Age group | |||||||
| 40–49 | 11.4 | 11.4 | 807 | 137 (32 to 226) | 1138 (342 to 1821) | 72 (0 to 332) | 2122 (1725 to 2597) |
| 50–59 | 48.5 | 43.1 | 7350 | 1132 (266 to 1865) | 4296 (1289 to 6873) | 270 (0 to 1254) | 8006 (6509 to 9802) |
| 60–69 | 58.1 | 44.8 | 11 320 | 1544 (363 to 2543) | 4435 (1331 to 7096) | 279 (0 to 1295) | 8265 (6720 to 10 119) |
| 70–75 | 21.5 | 14.4 | 7900 | 951 (224 to 1566) | 1409 (423 to 2254) | 88 (0 to 411) | 2625 (2134 to 3214) |
| Race/ethnicity | |||||||
| Non-Hispanic white | 107.3 | 87.0 | 21 230 | 2914 (686 to 4799) | 8657 (2597 to 13 850) | 544 (0 to 2528) | 16 132 (13 116 to 19 751) |
| Non-Hispanic black | 12.8 | 10.5 | 3640 | 505 (119 to 832) | 1044 (313 to 1671) | 66 (0 to 305) | 1947 (1583 to 2383) |
| Hispanic | 12.2 | 10.1 | 1670 | 230 (54 to 379) | 1010 (303 to 1616) | 63 (0 to 295) | 1883 (1531 to 2305) |
*Population = number of adults aged 40–75 years without ASCVD but with a ≥7.5% 10-year ASCVD risk in 100 000.
†Eligible population = number of adults aged 40–75 years without ASCVD but with ≥7.5% 10-year ASCVD risk multiplied by (1-prevalence of statin use).
‡The estimated excess number of myopathy cases was based on a meta-analysis of RCTs estimate of the excessive incidence of myopathy, 0.0628 per 1000 patient-years.7
§The estimated excess number of myopathy cases was based on a population-based cohort study with over 2 million patients.6 The excess incidence of myopathy per 1000 patient-years was 1.864 (95% CI 1.515 to 2.282) for men and 0.632 (95% CI 0.436 to 0.880) for women.
ASCVD, atherosclerotic cardiovascular diseases; NHANES, National Health and Nutrition Examination Survey; RCT, randomised clinical trial.